Company Overview and News

Stocks on a high

AS expected, the stock market had a relatively wild ride on Monday, its first day of business following the momentous 14th General Election (GE14).

Bursa Malaysia opens lower

2018-03-16 themalaymailonline
At 9.02am, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) stood at 1,843.48, declining 1.79 points from 1,845.27 at yesterday's close. — Picture by Azneal IshakKUALA LUMPUR, March 16 ― Shares on Bursa Malaysia opened lower this morning on the back of Wall Street’s meagre performance, coupled with global market participants' reluctance amid a trade uncertainty environment, dealers said.

Bursa Malaysia eases on nervousness over direction of us economic, foreign policies

2018-03-15 themalaymailonline
KUALA LUMPUR, March 15 — Bursa Malaysia closed at an intra-day low today on nervousness over the direction of US economic and foreign policies, leaving the local bourse in the red throughout the day, dealers said.

KL shares open lower

2018-03-15 themalaymailonline
KUALA LUMPUR, March 15 — Shares on Bursa Malaysia opened lower this morning in tracking Wall Street’s under performance, coupled with traders taking a risk aversion-stance, dealers said.

Bursa Malaysia rangebound in early trade

2017-04-11 themalaymailonline
At 9.30am, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) stood at 1,739.22, down 0.3 of-a-point from yesterday’s close of 1,739.52. — Reuters picKUALA LUMPUR, April 11 — Bursa Malaysia was rangebounds in early trade today on lack of catalyst amid geopolitical risk worries.

CAB, ManagePay, Advance Synergy, Asia Brands, Puncak Niaga

2017-03-21 theedgemarkets
KUALA LUMPUR (March 21): highlighted 16 stocks with momentum at Bursa Malaysia's afternoon market close today. Two stock showed positive momentum while 14 had negative momentum.   Stocks with positive momentum were:

Scomi Energy, Advance Synergy, Benalec, CCM, Evergreen, Goodway, Harbour-Link, JCY, Kelington, Kretam, Malton, Nylex, Orion, Rexit, Scomi Engineering, Seal, Eversendai, Signature, SSteel, Systech, WCE

2017-02-06 theedgemarkets
KUALA LUMPUR (Feb 6): highlighted 21 stocks with momentum at Bursa Malaysia's afternoon market close today. One stock showed positive momentum while 20 had negative momentum

Fire breaks out at one of ASB’s hotels in Switzerland

PETALING JAYA: A fire broke out at one of Advance Synergy Bhd’s (ASB) hotels in Switzerland owned by its indirect subsidiary.

Advance Synergy’s hotel hit by fire


Fire incident at Swiss hotel, an indirect 62.49%-owned unit of ASB

2017-01-03 theedgemarkets
KUALA LUMPUR (Jan 3): A fire incident occurred last Friday (Dec 30, 2016) at around 4:00 p.m. (1600 GMT) (local time in Arosa) at Holiday Villa Arosa located at Oberseepromenade, CH 7050 Arosa, Switzerland, a hotel owned by Posthotel Arosa AG, an indirect 62.49%-owned subsidiary of Advance Synergy Bhd (ASB).

Kerjaya, Pasdec, Advance Synergy, Mycron, Eonmetall

2016-05-03 theedgemarkets
KUALA LUMPUR (April 15): highlighted five stocks with momentum at Bursa Malaysia's afternoon market close today. Two stocks showed positive momentum while three had negative momentum.   Stocks with positive momentum were:

KLCI to face profit taking pressure

2016-03-09 themalaysianoutsider
The FBM KLCI is expected to face profit taking pressure today in line with the overnight decline at most global markets on the back of weaker economic…

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...